SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001395064-23-000010
Filing Date
2023-02-03
Accepted
2023-02-03 11:48:31
Documents
3

Document Format Files

Seq Description Document Type Size
1 SC 13G/A takedaschedule13gamendment.htm SC 13G/A 66822
2 EX-99.1 exhibit991ovid.htm EX-99.1 2181
3 EX-99.2 exhibit992ovid.htm EX-99.2 6048
  Complete submission text file 0001395064-23-000010.txt   76574
Mailing Address 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU TOKYO M0 103-8668
Business Address 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU TOKYO M0 103-8668 81332782111
TAKEDA PHARMACEUTICAL CO LTD (Filed by) CIK: 0001395064 (see all company filings)

IRS No.: 000000000
Type: SC 13G/A
SIC: 2834 Pharmaceutical Preparations

Mailing Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036
Business Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 212-776-4381
Ovid Therapeutics Inc. (Subject) CIK: 0001636651 (see all company filings)

IRS No.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-90350 | Film No.: 23584509
SIC: 2834 Pharmaceutical Preparations